Screened 2026-09-08 · the tape above runs as of 21:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Stryker Corporation holds its Distribution at $276.43. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-09-08
Phase
Distribution · caution
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$276.43
Valuation
28.68 trailing · 16.50 forward price to earnings
Values screen
PASS· score 83.2
Beta
0.77
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
33.15%
Below 33%
Interest-bearing debt is just 33.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.19%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
16.83%
Below 49%
Money owed to the company is 16.8% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades at roughly a 36% discount to our $375.30 fair value, moderate competitive moat, 9.40% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 35.8% margin of safety to the base estimate.
Third-party analyst targets: 25 covering, consensus Buy. The average target sits +38% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Stryker's Valuation Needs a Scalpel
Consider a world where every surgery, every joint replacement, relies on precision instruments. Stryker Corporation is that go-to toolkit, with a global footprint in medical technology. Operating through MedSurg and Neurotechnology and Orthopaedics segments, they cater to a broad spectrum of healthcare needs, from surgical equipment to patient safety solutions. Why it stands out is not just the breadth but the depth of its offerings, bolstered by a moderate competitive moat.
However, despite the robust 9% revenue growth and a healthy 14% profit margin, the stock is currently trading at a price that our analysis deems overvalued, with a forward P/E of 19.6x. While the market consensus is a 'buy' with a median target of $382, our fair value sits at $375.30, indicating a modest margin of safety of +14%. This suggests the market might be overenthusiastic about Stryker's prospects.
Risks are moderate, primarily due to the cyclical nature of the healthcare sector and the company's moderate moat, which could face challenges from new entrants or technological disruptions. While Stryker passes our ethical screen, investors should be mindful of the valuation, ensuring they're not paying a premium for a company already trading above our fair value estimate. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
SYK trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.8% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389.
2026-07-30Markup · changed$330.25+0.0%Entry 10
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-28Distribution$330.25+0.0%Entry 9
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-27Distribution$330.25+0.0%Entry 8
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-26Distribution$330.25+0.0%Entry 7
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-25Distribution$330.25+3.2%Entry 6
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-24Distribution$319.87+0.0%Entry 5
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-23Distribution$319.87+4.6%Entry 4
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-18Distribution$305.66+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389.
2026-07-03Distribution$305.66+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
